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Abstract:  
 
A fungal extract (MSX 63619), from the Mycosynthetix library of over 50,000 fungi, displayed 
promising cytotoxicity against a human tumor cell panel. Bioactivity-directed fractionation led to 
the isolation of an o-pyranonaphthoquinone decaketide, which we termed obionin B (1). The 
structure of 1 was deduced via spectroscopic and spectrometric techniques. The IC50 value of 1 
was moderate, ranging from 3 to 13 μM, depending on the cell line tested. 
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 Article: 
 
Nature, in general, and fungi, specifically, have and continue to be a valuable source of new drug 
leads.1, 2 and 3 For example, two of the most well known drug classes of the 20th century, 
antibiotics and cholesterol lowering agents, both originated as fungal secondary metabolites 
(e.g., penicillin and compactin). More recently, in 2010 the U.S. FDA approved a new treatment 
for multiple sclerosis, fingolimod (Gilenya), which derived from the fungal secondary 
metabolite, myriocin.4 Yet, despite these successes, it has been postulated that fewer than 10% of 
the estimated 1–1.5 million species of fungi in the world have been identified taxonomically, 
with possibly an even smaller percentage being studied for bioactive leads.5 Thus, given the 
under explored biodiversity, and the aforementioned successes as inspiration, our research team 
has been probing the Mycosynthetix library of filamentous fungi, representing over 50,000 
isolates, for new anticancer drug leads.6 
 
An extract of the filamentous fungus MSX 636197 exhibited promising cytotoxic activity, as 
evidenced by less than 20% survival of human tumor cells when treated with 20 μg/mL of crude 
extract. The 1:1 chloroform/methanol extract of the solid fermentation of MSX 63619 was 
subjected to bioactivity-directed fractionation using flash chromatography on silica gel followed 
by preparative RP-HPLC on C18.8 This resulted in the isolation (>95% purity according to 
HPLC) and characterization of a new decaketide that was named obionin B (1). This compound 
was evaluated against the human tumor panel and a pair of antibacterial assays. 
 
Compound 1,9 which was deep purple in color, displayed HRESIMS data of m/z355.1541 in the 
negative mode (corresponding to C21H24O5–H, calcd for 355.1545 [M−H]−), indicating an index 
of hydrogen deficiency of ten. The 1H and COSY NMR data showed signals consistent with a 
straight saturated alkyl chain from δH 0.8–2.3. The rest of the signals were singlets, starting with 
a three-proton singlet at δH 3.81, suggesting a methoxy group. A two-proton singlet was present 
at δH 5.16, followed by one-proton singlets at δH 5.56, 6.26, 6.30, and 12.31, the latter consistent 
with an intramolecular hydrogen bonded phenol. The 13C-NMR data showed 21 peaks, consistent 
with the HRMS data, including seven peaks upfield of δC 35, six of which were methylenes and 
the seventh a methyl according to the multiplicity edited HSQC experiment. These data indicated 
that the straight saturated alkyl chain was n-heptyl. The only other signals upfield of δC 100 were 
a methylene at δC 63.1 that correlated with the two-proton singlet at δH 5.16, and the methoxy 
signal at δC 55.9. The remaining signals were for sp2carbons, with five between δC 100–120, five 
between δC 130–170, and two between δC175–180 (see Supplementary data for the 1H and 13C 
NMR spectra and Table S1). 
 
Upon purification of 1, the diode-array detector on the HPLC displayed UV maxima at 243, 297, 
and 464 nm. A search of the Dictionary of Natural Products for the formula C21H24O5 and a UV 
range of 460–468 nm returned a single hit; obionin A.10 The downfield 1H and 13C NMR signals 
of 1 were in close agreement with the NMR data for the o-pyranonaphthoquinone portion of 
obionin A (2), except for the H-11 resonance, which was split into two one-proton doublets due 
to the presence of chiral centers in the side chain of 2; this was a two-proton singlet (δH 5.16) in 
achiral 1. However, the data for the upfield region were significantly different. Obionin A (2) has 
a branched saturated alkyl chain ( Fig. 1) instead of the n-heptyl chain of 1. The HMBC 
spectrum showed that the n-heptyl group of 1 was attached to the o-pyranonaphthoquinone at the 
same position (C-9) as the branched saturated chain in obionin A ( Fig. 2). To verify that the 
quinone was ortho instead of para, key HMBC correlations were observed from H-6 to C-4, and 
H-4 to both C-6 and C-2 ( Fig. 2). The remaining HMBC correlations ( Fig. 2) confirmed the 
structure of 1, which was termed obionin B in deference to the earlier studies on obionin A. 10 
 
 
Figure 1. Structure of obionin A (2) and obionin B (1) 
 
 
Figure 2. HMBC correlations of obionin B (1).  
 
Compound 1 was assayed against several human cancer cell lines using methods described 
previously,11 including the MCF-7 (breast carcinoma), NCI-H460 (large cell lung carcinoma), 
SF-268 (astrocytoma), HT-29 (colorectal adenocarcinoma), and MDA-MB-435 (melanoma) cell 
lines. The IC50 values (Table 1) indicated that obionin B was moderately cytotoxic. 
Compound 1 was inactive (MIC values >500 μg/mL; data not shown) when tested for 
antimicrobial activity using methods described previously11against Escherichia coli and Bacillus 
subtilis. Previously, obionin A (2) was isolated based on the brine shrimp toxicity of the fungal 
extract, 10 although the authors stated that 2 did ‘not account for that activity;’ to the best of our 
knowledge, 2 has not been examined for cytotoxicity. A related pair of o-
pyranonaphthoquinones, the laccaridiones, were reported as promising antimycotic leads due to 
the inhibition of Candida albicansadhesion to epithelial and endothelial cells, as well as the 
ability to reduce the release and inhibit the catalytic activity of secreted aspartic 
proteases. 12 These effects resulted in reduced virulence properties (e.g., colonization and 
penetration of host tissues) without being fungistatic or fungicidal. 12 However, only laccaridione 
B has been investigated for cytotoxicity toward human tumor cells, with IC50 values ranging 
from 4.5 μM in the K-562 human erythroleukemia cell line to 34 μM in HeLa cervical carcinoma 
cells. 13 In comparison, obionin B (1) exhibited broad potency at the lower end of this range 
(Table 1). 
 
 
 
In conclusion, an o-pyranonaphthoquinone decaketide (obionin B, 1) has been isolated and 
characterized from a terrestrial fungus from the Mycosynthetix library of filamentous 
fungi; 1 exhibited moderate cytotoxicity toward a panel of five human tumor cell lines (Table 1). 
Compound 1 is structurally related to the known nonaketides obionin 
A, 10leptosphaerodione, 14 and the laccaridiones. 13 Interestingly, the former two were both 
isolated from marine-derived fungi of the same order (Pleosporales) as the terrestrial fungus 
(MSX 63619) 7 investigated herein. 
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Figure S1. 1H NMR (500 MHz) and 13C NMR (125 MHz) of Obionin B (1) in CDCl3 
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Table S1. 1H NMR (500 MHz) and 13C NMR (125 MHz) data for Obionin B (1) in CDCl3 
Position Obionin B (1) 
 δC δH mult (J in Hz) 
1 179.0 --- 
2 177.3 --- 
3 151.8 --- 
4 114.0 6.26, s 
5 135.2 --- 
6 117.4 6.30, s 
7 144.3 --- 
8 100.8 5.56, s 
9 167.3 --- 
11 63.1 5.16, s 
 
12 111.7 --- 
13 162.4 --- 
14 111.1 --- 
1ʹ 34.5 2.23, t (7.6) 
2ʹ 27.0 1.57, pent (7.6) 
3ʹ 29.2* 1.22-1.37, m 
4ʹ  29.3* 1.22-1.37, m 
5ʹ 31.9 1.22-1.37, m 
6ʹ 22.8 1.22-1.37, m 
7ʹ 14.3 0.88, t (7.6) 
-OCH3 55.9 3.81, s 
13-OH --- 12.31, s 
* Assignments can be interchanged. 
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